Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia

• Published in: The Journal of biological chemistry Vol. 286; no. 18; pp. 16101 - 16108
• Main Authors: Cenik, Basar, Sephton, Chantelle F, Dewey, Colleen M, Xian, Xunde, Wei, Shuguang, Yu, Kimberley, Niu, Wenze, Coppola, Giovanni, Coughlin, Sarah E, Lee, Suzee E, Dries, Daniel R, Almeida, Sandra, Geschwind, Daniel H, Gao, Fen-Biao, Miller, Bruce L, Farese, Jr, Robert V, Posner, Bruce A, Yu, Gang, Herz, Joachim
• Format: Journal Article
• Language: English
• Published: United States American Society for Biochemistry and Molecular Biology 06.05.2011
• Subjects: Dose-Response Relationship, Drug; Frontotemporal Dementia - drug therapy; Frontotemporal Dementia - metabolism; HEK293 Cells; Histone Deacetylase Inhibitors - pharmacology; Humans; Hydroxamic Acids - pharmacology; Intercellular Signaling Peptides and Proteins - biosynthesis; Neurobiology; Progranulins; Transcription, Genetic - drug effects; Up-Regulation - drug effects; Vorinostat

Progranulin (GRN) haploinsufficiency is a frequent cause of familial frontotemporal dementia, a currently untreatable progressive neurodegenerative disease. By chemical library screening, we identified suberoylanilide hydroxamic acid (SAHA), a Food and Drug Administration-approved histone deacetylas...